英药厂阿斯利康夥墨西哥及阿根廷药企生产最少4亿剂新冠疫苗
《路透》报道,英国药厂阿斯利康(AstraZeneca)墨西哥主管Sylvia Varela表示,公司与墨西哥及阿根廷政府合作,计划在拉丁美洲生产1.5亿剂新冠疫苗,最终生产最少4亿剂於区内分发。她指出,公司优先协助最有需要援助人士,预计每剂疫苗价格不会超过4美元,意味首1.5亿剂疫苗售价约6亿美元。
她亦表示,疫苗的第三阶段测试已在美国、南非、英格兰及巴西进行,预计11月或12月完成,其後会寻求政府批准生产出售,并把技术向阿根廷INSUD Group及墨西哥Laboratorios Liomont转移,於明年首季启动生产。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.